Farmas USA

Yo tnia apuntado q exel era lunes y martes, lo mirare a ver

si podeis ir comentando a grandes rasgos, cuando podais, que va pasando en ASCO, los que vamos con el movil, y vamos justitos de ingles, os lo agradadeceriamos de todo corazon.
el lunes puede ser un gran dia!!

No se si estará bien, pero yo miré esto:

Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT) (Poster Discussion, Abstract #535, Poster Board #25) Saturday, June 2, 2012 - 1:15pm CDT

Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC) (Poster, Abstract #5547, Poster Board #22G) Saturday, June 2, 2012 - 1:15pm CDT

Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT) (Poster Discussion, Abstract #8531, Poster Board #20) Saturday, June 2, 2012 - 1:15pm CDT

Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC) (Oral Presentation, Abstract #4504) Saturday, June 2, 2012 - 4:15pm CDT

Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT) (Oral Presentation, Abstract #4007) Saturday, June 2, 2012 - 5:15pm CDT

Investigator sponsored trial of efficacy and tolerability of cabozantinib (cabo) at lower dose: A dose-finding study in men with castration-resistant prostate cancer (CRPC) and bone metastases (Poster Discussion, Abstract #4566, Poster Board #20) Monday, June 4, 2012 - 8:00am CDT

An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline (Oral Presentation, Abstract #5508) Monday, June 4, 2012 - 11:30am CDT

Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT) (Poster Discussion, Abstract #7514, Poster Board #4) Tuesday, June 5, 2012 - 8:00am CDT

Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE) (Oral Presentation, Abstract #4513) Tuesday, June 5, 2012 - 11:00am CDT

http://www.exelixis.com/resources/events/asco-2012

En directo, el mismo que seguía el panel de ARNA!!!

http://www.coveritlive.com/index2.php?option=com_altcaster&task=viewaltcast&altcast_code=be03e11d36&ipod=y

JNJ reporta 50% de mayor efectividad en cancer de próstata. Con Zytiga. Puede tener algo de repercusión.

Prometeo, perdona por el off topic, pero que broker usas para el mercado internacional??

Te cuento, yo estoy con R4, pero soy un mini-especulador, juego con poca pasta(la que tengo,jiji) y ahora con las nuevas comisiones no me merece la pena...en fin...ya me dices

Saludos y gracias

50% mas de efectividad me parece una barbaridad.
Se echa de menos a jorge a. Para que lo valore mejor.

Mediana. Mejor dicho